Stockreport

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults [Yahoo! Finance]

ZyVersa Therapeutics, Inc.  (ZVSA) 
PDF adults (60 years) who were cognitively normal at baseline but demonstrated cognitive decline one year later (N I ) compared to ASC levels in those who: Were cognitivel [Read more]